Loyal's Large-Scale Clinical Trial Aims to Extend Dog Lifespan

• Loyal is conducting a clinical trial to evaluate a daily chewable medication aimed at extending the lifespan and improving the quality of life for dogs aged 10 years and older, weighing at least 14 pounds.
• The trial spans up to four years, requiring owners to administer the medication daily and complete surveys on their dog's well-being, either at the vet clinic or remotely.
• Participating owners must commit to transferring their dog's primary care to the study clinic, involving six visits in the first year and two visits annually for the remaining duration of the study.

Loyal, a company focused on developing drugs to extend the lifespan of dogs, has initiated a large-scale clinical trial to assess the efficacy of a novel medication. The study aims to determine if a daily chewable medication can extend lifespan and improve the quality of life for older dogs.

Trial Design and Eligibility

The clinical trial is designed for dogs aged 10 years or older, weighing 14 pounds or more. Participating owners must commit to a study lasting up to four years. The study involves administering a flavored chewable medication daily and completing brief surveys about the dog's quality of life. These surveys can be completed at the vet clinic or remotely via smartphone, tablet, or computer.

Study Requirements

Owners participating in the trial are required to transfer their dog's primary care to the designated study clinic. The trial protocol includes six clinic visits in the first year, followed by two visits per year for the remaining years of the study. This comprehensive approach allows for close monitoring of the dogs' health and response to the medication.